Evidence map›Paper›PMID 37039683›Full record

ArticleMicrobiology spectrum2023

Identification of Fungus-Derived Natural Products as New Antigiardial Scaffolds.

Matthew A Hulverson, Samantha A Michaels, Jin Woo Lee, Karen L Wendt, Linh T Tran, Ryan Choi, Wesley C Van Voorhis, Robert H Cichewicz, Kayode K Ojo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Advances in pharmacological and pharmaceutical sciences · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Matthew A HulversonDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.ORCID 0000-0002-3413-4969
Samantha A MichaelsDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
Jin Woo LeeCollege of Pharmacy, Duksung Women's University, Seoul, Republic of Korea.
Karen L WendtNatural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma, USA.
Linh T TranDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
Ryan ChoiDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
Wesley C Van VoorhisDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.
Robert H CichewiczNatural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma, USA.
Kayode K OjoDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, Washington, USA.ORCID 0000-0002-2007-2170
University of Washington · USUniversity of Oklahoma · USDuksung Women's University · KR

Funding

Methionyl-tRNA Synthetase inhibitors can be developed as novel Giardiasis therapeuticsR01AI158524 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2021 to 2024
$2.8M
Development of Cell-active Giardia lamblia Methionyl-tRNA Synthetase Inhibitors as a New Therapeutic for GiardiasisR56AI146067 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2020 to 2020
$766k
Development of Dual Efficacy Therapeutic Against Cryptosporidiosis and GiardiasisR21AI140881 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2019 to 2020
$477k
NIAID NIH HHS R01 AI158524NIAID NIH HHS R21 AI140881NIAID NIH HHS R56 AI146067
6 · The paper itself

Abstract

There is an unmet need for effective therapies for treating diseases associated with the intestinal parasite Giardia lamblia. In this study, a library of chemically validated purified natural products and fungal extracts was screened for chemical scaffolds that can inhibit the growth of G. lamblia. The phenotypic screen led to the identification of several previously unreported classes of natural product inhibitors that block the growth of G. lamblia. Hits from phenotypic screens of these naturally derived compounds are likely to possess a variety of mechanisms of action not associated with clinically used nitroimidazole and thiazolide compounds. They may therefore be effective against current drug-resistant parasite strains.

Indexed as

Antiprotozoal AgentsBiological ProductsGiardiasisChildFungiHumansMetronidazoleAntiprotozoal AgentsBiological ProductsMetronidazoleantigiardialfungal extractsGiardia lambliapure natural compounds

Identifiers

PMID37039683
PMCPMC10269678
OpenAlexW4364354248

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.